Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 48.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,568 shares of the biopharmaceutical company's stock after purchasing an additional 23,898 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.06% of Alnylam Pharmaceuticals worth $20,233,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $26,000. Allspring Global Investments Holdings LLC grew its position in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Friedenthal Financial bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $51,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 95.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 0.0 %

NASDAQ:ALNY traded down $0.12 during mid-day trading on Thursday, reaching $272.89. The company's stock had a trading volume of 302,105 shares, compared to its average volume of 870,989. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The stock has a fifty day moving average of $274.17 and a 200-day moving average of $229.04. The firm has a market capitalization of $35.20 billion, a PE ratio of -104.20 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The business's revenue was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALNY shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Barclays boosted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Raymond James increased their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Finally, Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $294.50.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company's stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.